Johnson & Johnson (NYSE:JNJ) Stake Reduced by Advantage Trust Co

Advantage Trust Co reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 845 shares of the company’s stock after selling 136 shares during the quarter. Advantage Trust Co’s holdings in Johnson & Johnson were worth $140,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lantz Financial LLC raised its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $453,000. Joel Isaacson & Co. LLC raised its stake in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares in the last quarter. State of Wyoming raised its stake in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after buying an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC raised its stake in shares of Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock worth $2,635,000 after buying an additional 2,529 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on JNJ shares. Guggenheim reissued a “neutral” rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Finally, Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $168.29 on Friday. The firm has a market cap of $404.92 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The stock’s 50-day moving average is $156.08 and its 200-day moving average is $155.88. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.